EMA selected TrialAssure’s ANONYMIZE platform as an official anonymization tool to redact public clinical trial documents under Policy 0043. The AI-assisted system will be used to protect participant identities when market authorization holders post clinical dossiers. TrialAssure said the workflow combines automated detection with expert oversight, and is designed to remain auditable while preserving scientific utility across documents, datasets, and images. For sponsors and trial stakeholders, the selection signals a concrete path to reconcile transparency requirements with privacy controls, potentially reducing friction in public posting timelines.